Union Bancaire Privee’s Carisma Therapeutics CARM Stock Holding History

Union Bancaire Privee’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4	Hold	785	–	–	﹤0.01%	487
2026 Q1	$22	Hold	785	–	–	﹤0.01%	481
2025 Q4	$28	Buy	785 +250	+47%	+$63	﹤0.01%	491
2025 Q3	$131	Hold	535	–	–	﹤0.01%	474
2025 Q2	$190	Hold	535	–	–	﹤0.01%	486
2025 Q1	$163	Hold	535	–	–	﹤0.01%	504
2024 Q4	$227	Buy	+535	New	+$441	﹤0.01%	566

Union Bancaire Privee's CARM Position: Q2 2026 in Review

Union Bancaire Privee held its Carisma Therapeutics (CARM) position steady in Q2 2026 at 785 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #487.

Union Bancaire Privee first reported a position in CARM in Q4 2024 and has held it in 7 quarters since. The position peaked at $227 in Q4 2024. 1 fund tracked by Wall St. Rank holds CARM as of Q2 2026.

Union Bancaire Privee held 785 shares of Carisma Therapeutics worth $4 as of Q2 2026.
Union Bancaire Privee left its Carisma Therapeutics share count unchanged in Q2 2026.
Carisma Therapeutics made up ﹤0.01% of Union Bancaire Privee's portfolio in Q2 2026, its #487 holding.
Union Bancaire Privee first reported a position in Carisma Therapeutics in Q4 2024 and has held it in 7 quarters since.
Union Bancaire Privee's Carisma Therapeutics position peaked at $227 in Q4 2024.
1 fund tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2026.

Based on Union Bancaire Privee's 13F filing for Q2 2026, filed 16 Jul 2026.